Health risk information management device, computer and recording medium

Abstract

The present invention comprises: an expected health risk information acquisition unit, which acquires information related to the expected health risk of the user; and a cultured cell preparation determination unit, which determines whether to prepare cultured cells derived from the user's cells based on the expected health risk information.

Description

[0001] Cross-references to related applications

[0002] This application is based on Japanese application No. 2018-239868 filed on December 21, 2018, and the contents of the Japanese application are cited herein. Technical Field

[0003] The invention relates to a health risk information management device, a computer and a recording medium. Background Art

[0004] In recent years, expectations for regenerative medicine using iPS cells have increased. On the other hand, there are known technologies for estimating future health risks based on genomic information and / or biological information such as blood pressure, and activity information such as exercise volume, as described in Patent Document 1. It is expected that a mechanism for preparing for future treatments based on regenerative medicine will be realized based on such future health risks.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent Application Publication No. 2017-097895 Summary of the invention

[0008] Since the preparation of iPS cells is very expensive, it is desirable to provide users with proposals based on accurate information about future health risks (such as what kind of iPS cells should be produced by what age? How likely is it that the risk can be reduced by this, etc.).

[0009] Therefore, the purpose of the present invention is to utilize stem cells to accurately predict future health risks and to realize a mechanism related to preparing for future health risks.

[0010] The health risk information management device of the present invention comprises: an expected health risk information acquisition unit, which acquires information related to the expected health risk of the user; and

[0011] A cultured cell preparation determination unit determines whether to prepare cultured cells derived from the user's cells based on the information on the expected health risk.

[0012] The health risk information management method of the present invention comprises the steps of: obtaining information related to the expected health risk of the user; and

[0013] The step of determining whether to prepare cultured cells derived from the user's cells based on the information on the expected health risks.

[0014] The program of the present invention enables a computer to function as an expected health risk information acquisition unit and a cultured cell preparation determination unit, wherein the expected health risk information acquisition unit acquires information related to the expected health risk of the user, and the cultured cell preparation determination unit determines whether to prepare cultured cells derived from the user's cells based on the expected health risk information.

[0015] Effects of the Invention

[0016] According to the present invention, it is possible to utilize stem cells to accurately predict future health risks and realize a mechanism related to preparing for future health risks. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a block diagram showing the structure of the health risk information management device 10 according to the embodiment of the present invention.

[0018] Figure 2 1 is a block diagram showing functional modules implemented by the control device 11 of the health risk information management device 10 according to the embodiment of the present invention.

[0019] Figure 3 This is a flowchart of a process of proposing somatic cell preparation based on health risk information of a user, which is performed by the health risk information management device 10 according to an embodiment of the present invention.

[0020] Figure 4 This is a flowchart of a process of proposing an iPS cell bank based on a confirmation experiment of health risks using somatic cells prepared via iPS cells and the results of the confirmation experiment according to an embodiment of the present invention.

[0021] Figure 5 This is a flowchart of the HLA homozygous donor search process according to the embodiment of the present invention.

[0022] Explanation of symbols

[0023] 10: Health risk information management device

[0024] 11: Control device

[0025] 12: External storage device

[0026] 20: Cell preparation management system

[0027] 30: User terminal

[0028] 101: Anticipated health risk information acquisition department

[0029] 102: Somatic cell type determination

[0030] 103: Recommended inspection content determination department

[0031] 104: Somatic cell preparation instructions

[0032] 105: Inspection result providing department

[0033] 106: Confirmation of whether cell preparation is necessary

[0034] 107: Health risk response information provision department

[0035] 108: Donor candidate extraction department

[0036] 109: Receptor Information Acquisition Department

[0037] 110: HLA matching determination unit

[0038] 111: Matching information provider

[0039] 112: Matcher Count Calculation Department

[0040] 113: Donor Cell Preparation Management Department

[0041] 114: Cultured Cell Preparation and Judgment Department

[0042] 121: Customer information database DETAILED DESCRIPTION

[0043] Next, a mode for carrying out the present invention will be described in detail with reference to the drawings.

[0044] Figure 1 1 is a block diagram showing the structure of the health risk information management device 10 according to an embodiment of the present invention. Figure 1 As shown, the health risk information management device 10 includes a control device 11 and an external storage device 12 .

[0045] The control device 11 includes, as hardware, a CPU, a memory such as ROM and / or RAM, an input interface, an output interface, a communication interface, etc. The control device 11 implements various functions by the CPU executing a program stored in the ROM, etc. The external storage device 12 is a hard disk drive, etc. A customer information database 121 is installed in the external storage device 12.

[0046] The health risk information management device 10 does not have to be composed of one computer, but may be composed of a plurality of computers and / or external storage devices distributed on a communication network. Figure 1 As shown, the health risk information management device 10 is connected to the cell preparation management system 20 and the user terminal 30 via a communication line N.

[0047] Figure 21 is a block diagram showing functional modules implemented by the control device 11 of the health risk information management device 10. The functional modules include: an expected health risk information acquisition unit 101, a somatic cell type determination unit 102, a recommended examination content determination unit 103, a somatic cell preparation instruction unit 104, an examination result providing unit 105, a cell preparation necessity confirmation unit 106, a health risk corresponding information providing unit 107, a donor candidate extraction unit 108, a recipient information acquisition unit 109, an HLA matching determination unit 110, a matching information providing unit 111, a matching number calculation unit 112, a donor cell preparation management unit 113, and a cultured cell preparation determination unit 114.

[0048] The customer information database 121 has registered information of the user, and the user registers his / her own health risk information and / or iPS cell bank information in the health risk information management device 10. Specifically, for example, in addition to the user ID (user identification information), name, gender and / or date of birth, contact information (email address, telephone number, etc. of the user terminal 30), it also includes: information related to genetic examination and / or health risks (diseases that may be contracted, probability of disease onset, expected onset period, HLA type, etc.), information related to the stored iPS cells and / or somatic cells (identification number, type of somatic cells, number of stored cells, preparation period, etc.), etc.

[0049] The cell preparation management system 20 manages the preparation of iPS cells derived from the user's somatic cells (e.g., autologous cells, cells for autotransplantation). The cell preparation management system 20 is preferably a dedicated device capable of making iPS cells, but is not limited thereto, and also includes a system for managing the preparation of iPS cells in medical institutions, research institutions, and other preparation institutions capable of making iPS cells. A dedicated device capable of making iPS cells refers to a device that can separate somatic cells (separation of peripheral blood mononuclear cells from blood and / or separation of fibroblasts from skin slices, etc.) and expand the culture of separated cells in a closed space without artificial induction, culture, preservation, and recording of iPS cells, and at least one, preferably two or more, of the devices. In addition, it is preferred to also separate the user's somatic cells that are the basis of cell preparation (separation of peripheral blood mononuclear cells from blood, separation of fibroblasts from skin slices, etc.), and expand the culture of separated cells. The cell preparation management system 20 can be set in the same device as the health risk information management device 10, or it can be set in a device different from the health risk information management device 10.

[0050] The cell preparation management system 20 prepares iPS cells by introducing induction factors into somatic cells collected from the user based on instructions from the health risk information management device 10, etc., and performs quality tests on the prepared iPS cells (differentiation induction ability test, gene mutation test, fungus, bacteria, virus test, etc.) to prepare iPS cells that meet the standards. The iPS cells prepared in this way are stored under appropriate temperature management. It should be noted that in addition to the preparation of iPS cells, the cell preparation management system 20 can also prepare specific somatic cells from iPS cells. For example, the cell preparation management system 20 can prepare iPS cells from the user's skin tissue, and further, it can prepare various somatic cells from the prepared iPS cells. The somatic cells include: for example, nervous system cells, myocardium, liver cells, β-cells, blood cells, platelets, skin cells, mesenchymal cells, etc. In addition, in the cell preparation management system 20, the implementation of health risk confirmation experiments using somatic cells prepared from iPS cells can also be managed. Furthermore, the cell preparation management system 20 may also perform a verification experiment on the compatibility between somatic cells prepared from iPS cells of a donor candidate and immune cells derived from the recipient's blood based on an instruction from the health risk information management device 10 .

[0051] The user terminal 30 is a terminal held by a user who has registered information in the health risk information management device 10. The user terminal 30 can utilize all terminal devices such as a personal computer (PC), a notebook PC, a tablet terminal, a smart phone, a mobile phone, a portable information terminal (PDA), etc., which can send and receive data with the health risk information management device 10 via a communication network. The user terminal 30 has: a processor, a keyboard and / or a mouse, various operation buttons and / or an input device such as a touch panel, a display device such as a liquid crystal display, a communication interface for connecting to a communication network, and storage resources such as a hard disk drive or a semiconductor memory (ROM, RAM, etc.).

[0052] (Proposal processing for somatic cell preparation)

[0053] Next, use Figure 3 The flowchart of will explain the proposal process of somatic cell preparation based on the health risk information of the user performed by the health risk information management device 10.

[0054] First, the health risk information management device 10 first obtains information related to the expected health risks of the user (S101). The information related to the expected health risks is information inferred based on the results of, for example, genetic examinations. Genetic examinations include: examinations of genomic information such as whole exome sequences (WES), whole genome sequences (WGS), SNP arrays, and examinations of gene expression information, MicroRNA expression information, HLA types, etc., and / or sequence examinations. The expected health risks include information about diseases that the user (examination subject) and / or his family may have in the future and the probability of onset. The information on expected health risks can be obtained from a system such as an institution that performs genetic examinations via a communication line, or it can be input by a technician and / or manager operating the health risk information management device 10 with reference to the user's examination data.

[0055] Next, the health risk information management device 10 determines the type of somatic cells that should be prepared from cultured cells derived from the user's cells in order to confirm the acquired expected health risks of the user (S102). Here, the cultured cells are specifically iPS cells, but can also be other stem cells, pluripotent stem cells, and adult stem cells. For example, in the case of a user who is expected to have a high risk of developing Alzheimer's disease, neural cells are determined as the somatic cells that should be prepared, in the case of a user who is expected to have a high risk of developing rheumatic disease, cells of cartilage tissue are determined as the somatic cells that should be prepared, and in the case of a user who is expected to have a high risk of developing myocardial infarction, cardiomyocytes are determined as the somatic cells that should be prepared. In addition, health risks are not limited to specific disease names, and for example, also include information such as poor UV resistance of the skin and the skin is prone to drying if exposed to ultraviolet rays. In this case, skin cells are determined as the somatic cells that should be prepared.

[0056] Further, the health risk information management device 10 determines the content of the examination that should be performed using the prepared somatic cells in order to confirm the expected health risks of the user (S103). For example, in the case where the risk of Alzheimer's disease is high, an experiment is performed to expose the prepared neural cells to hydrogen peroxide, etc. to confirm the vulnerability to oxidative stress. In addition, in the case where the risk of rheumatic disease is high, an experiment is performed to find out whether the symptoms of rheumatic disease appear using cells of the prepared cartilage tissue. In addition, in the case where the risk of myocardial infarction is expected to be high, an experiment is performed to verify whether myocardial infarction actually occurs using the prepared cardiomyocytes. In addition, in the case where the UV resistance of the skin is weak, UV is irradiated to the prepared skin cells to confirm the reaction, or a drying test is performed to confirm the weakness to drying. In addition, confirmation is also effective in the case of high risk of ALS (amyotrophic lateral sclerosis) and / or Parkinson's disease, skin diseases, neurological diseases, eye diseases, heart diseases, liver diseases, kidney diseases, blood diseases, etc. In addition, not only can the risk of disease be confirmed, but also the responsiveness (allergic reaction and / or allergy, etc.), presence or absence of allergy, toxicity, etc. of existing drugs applicable to these diseases can be verified, and which drug combination is the most effective can be verified. In this way, the susceptibility of diseases and / or symptoms, effective treatment methods and / or prevention methods can be verified using actual prepared somatic cells. In addition, the risk of GVHD (graft versus host disease) after transplantation can also be verified.

[0057] Next, the health risk information management device 10 transmits information on somatic cells to be prepared for a test to verify the expected health risk to the user terminal 30 of the user ( S104 ), and receives a response whether the user wishes to prepare somatic cells and conduct the test ( S105 ).

[0058] When the health risk information management device 10 receives a reply indicating that the user wishes to prepare somatic cells and conduct a test ( S106 : Yes), it transmits a somatic cell preparation instruction to the cell preparation management system 20 ( S107 ).

[0059] (Experiments to verify health risks of using somatic cells generated through iPS cells and proposals for iPS cell banks based on the results of the experiments)

[0060] Next, use Figure 4 The flowchart of the present invention describes the verification experiment of the health risks of using somatic cells prepared through iPS cells and the proposal process of iPS cell bank based on the results of the verification experiment. Figure 4Each step of S201 to S205 shown is automatically performed by the cell preparation management system 20. In addition, the work flow may be automatically performed by the cell preparation management system 20 or may be performed by an operator based on a work instruction presented by the cell preparation management system 20.

[0061] In the cell preparation management system 20, first, iPS cells of the user are prepared (S201), and then somatic cells for health risk verification experiments are prepared from the iPS cells (S202). The prepared iPS cells and somatic cells are managed in a manner of marking labels (identification numbers). The information of the labels of the iPS cells and somatic cells is also provided to the health risk information management device 10 and registered in the customer information database 121 (S203).

[0062] Furthermore, the somatic cells prepared in the cell preparation management system 20 are used to implement experiments of the disease reproduction model (S204). Specifically, according to the content determined by step S103, experiments are conducted to verify the probability of the disease that is expected to be risky. In addition, the period until the onset of the disease is predicted. In addition, using the prepared somatic cells, screening of drugs and / or drug combinations that are effective in improving the symptoms is performed (S205). Specifically, verification is performed on what kind of drugs are effective, what kind of drug combinations are effective, and what the toxicity and / or allergy of the drugs are. The information on the experimental results (probability of onset, expected period until onset) obtained based on the disease reproduction model and the results of drug screening is registered in the customer information database 121.

[0063] The health risk information management device 10 prepares for the situation in which the disease actually occurs in the future based on the experimental results obtained based on the disease reproduction model, and pre-calculates the recommended preparation period of iPS cells or somatic cells prepared from iPS cells and the effect (probability) of eliminating health risks through the preparation of the somatic cells (S206).

[0064] The health risk information management device 10 sends the results of the verification experiment using somatic cells to the user terminal 30 of the user (probability of onset, expected period until onset) (S207). In addition, together with the results of the examination, at least one of the following is provided: information on somatic cells that should be prepared and stored in advance in preparation for future disease onset, recommended preparation period, and information on quantification of the effect obtained by the preparation of the somatic cells (S208). Furthermore, the health risk information management device 10 provides at least one of the following information: the required treatment costs based on the expected period until the onset of the disease, and a payment plan (including a savings plan) for the treatment costs corresponding to the period until the onset.

[0065] Next, use Figure 5The flowchart of the following illustrates the donor retrieval process for HLA homozygotes. In this embodiment, in accordance with the request of a person who wishes to provide somatic cells from a donor (hereinafter referred to as a recipient), an HLA type-matched donor is retrieved from among users whose data are managed by the health risk information management device 10. The recipient can be a user whose data is managed by the health risk information management device 10, or an unregistered person. In addition, the retrieval of HLA type-matched donors can also be performed using other databases.

[0066] (HLA homozygous donor search process)

[0067] First, the health risk information management device 10 extracts HLA homozygous users from the users registered in the customer information database 121 (S301). The extracted users become donor candidates. It should be noted that in addition to the users registered in the customer information database 121, data managed by a genetic testing company and / or prenatal diagnosis data, data managed by a bone marrow bank, an HLA typing database, etc. can also be used to extract donor candidates from users whose HLA information is recorded in these data.

[0068] Next, the health risk information management device 10 obtains the information of the recipient's HLA type (S302), and extracts the donor candidate whose HLA type matches the recipient's HLA type from the extracted donor candidates (S303). It should be noted that the extraction of donor candidates has nothing to do with whether they are HLA homozygous, and people whose HLA type is similar to the recipient's HLA type can also be extracted.

[0069] The health risk information management device 10 can provide the recipient with information on HLA type-matched donor candidates (S304). Specifically, the information can be sent to the user terminal 30 held by the recipient via e-mail or printed out as a report.

[0070] If the donor candidate is determined, a matching verification experiment is performed in an inspection agency or the like by mixing somatic cells prepared from the iPS cells of the donor candidate with immune cells derived from the recipient's blood in a test tube (S305). The matching verification experiment can be implemented by the cell preparation management system 20 based on instructions from the health risk information management device 10. Alternatively, it can be implemented by an operator based on an operation instruction prompted by the health risk information management device 10. The results of the matching experiment can be provided to the recipient via the health risk information management device 10 (S306). In addition, information related to the health risks of the donor (what is the probability of contracting what disease?) can also be provided together with the results of the matching experiment.

[0071] It should be noted that the health risk information management device 10 can also calculate the number of recipients who obtain the HLA type matching result for each HLA homozygous user (donor candidate) based on the data obtained from the donor search process performed in accordance with the request from multiple recipients. Furthermore, for each donor candidate, it is also possible to estimate how many iPS cells of the donor candidate are needed based on the number of HLA type matching recipients, and provide the estimated results to the cell preparation management system 20. In the cell preparation management system 20, the iPS cells of each donor candidate can be prepared and / or expanded based on the estimated results.

[0072] (Judgment of Cultured Cell Preparation)

[0073] The health risk information management device 10 also has a function of judging whether to prepare cultured cells derived from cells (including somatic cells, stem cells, mesenchymal stem cells, blood cells, epithelial cells, etc.) of the user based on the information obtained about the expected health risks of the user. As in the above embodiment, the cultured cells are specifically iPS cells, but they can also be other stem cells, pluripotent stem cells, and adult stem cells. Thus, it is possible to accurately judge whether iPS cells should be prepared and stored in advance according to the degree and / or severity of the possibility of the user's future health risks. As an example of judging that it is effective to prepare iPS cells in advance, for example, the situation of using iPS cells for effective treatment when the actual disease occurs can be cited. In addition, in the case of diseases with a high tendency to be inherited between blood-related people, when blood-related people such as parents and / or brothers are at risk of these diseases, the determination result that the storage of iPS cells is effective can also be given to other people who are blood-related people. It should be noted that the preparation of cells can also include cell initialization, reprogramming, cell fate conversion, and cell transformation.

[0074] In addition, the health risk information management device 10 also has information on the user's HLA type to determine whether to prepare cells derived from the user's somatic cells. Specifically, for HLA homozygous users, since there is a possibility of becoming a donor, it can also be determined that the preparation and storage of iPS cells is effective.

[0075] As described above, based on the expected health risks and / or HLA type information based on genetic testing, it is determined whether the user is recommended to prepare and store iPS cells, thereby making appropriate recommendations efficiently. In particular, since the preparation and storage of iPS cells are expensive, recommendations based on accurate information are important. In addition, iPS cells can be prepared for people who really need them first, so that resources such as the cell preparation management system 20 can be effectively used.

[0076] As described above, according to this embodiment, it is possible to provide a mechanism for determining the type of somatic cells to be prepared from iPS cells derived from the user's somatic cells in order to verify the user's expected health risks based on genetic information, etc., and for performing tests for verifying the expected health risks using the prepared somatic cells. Thus, iPS cells can be utilized to accurately predict future health risks.

[0077] Furthermore, after providing the user with information on somatic cells required for examination, a mechanism is realized in which a user is asked whether or not to prepare and examine iPS cells and / or somatic cells derived from iPS cells, and when an answer indicating the desired meaning is received, the preparation of somatic cells is instructed to the cell preparation management system 20. Thus, the preparation and examination of iPS cells can be efficiently managed in accordance with the user's wishes.

[0078] In addition, based on the results of the examination using somatic cells, information on somatic cells that the user should prepare and store in advance to prepare for the occurrence of future diseases and / or the recommended preparation period, and information that quantifies the effect obtained by the preparation of the somatic cells. This can provide the user with judgment materials for making appropriate preparations for future health risks. Specifically, one's own iPS cells can be used as a judgment basis for whether to prepare and store in advance for the future.

[0079] Furthermore, since drugs and / or drug combinations that are effective in improving expected health risks are verified using the prepared somatic cells and the information is provided to users, somatic cells prepared from iPS cells can be effectively utilized.

[0080] In addition, the following mechanism is realized: the user of HLA homozygote is extracted as a donor candidate, and the donor candidate whose HLA type matches the HLA type of the recipient who wishes to provide somatic cells from the donor is extracted from the donor candidate. Thus, it is possible to efficiently search for a donor whose HLA type matches the HLA type of the recipient. In addition, since a mechanism is realized for verifying the compatibility using immune cells derived from the blood of the recipient and somatic cells derived from iPS cells of the donor candidate whose HLA type matches the HLA type of the recipient, and providing the verification result, it is possible to accept the provision of somatic cells from the donor on the basis of the verification of immune rejection reaction in advance. It should be noted that the extraction of the donor candidate has nothing to do with whether it is an HLA homozygote, and people whose HLA type is similar to the HLA type of the recipient can also be extracted. For example, as an example, there are about 15 types of HLA, and it is generally believed that if 4 of them match, it can be solved by the use of weak immunosuppressants, and if 6 match, no immunosuppressants are required. Therefore, it is also possible to extract donor candidates based on the information of how many types of HLA matches. It should be noted that the criteria for determining whether or not HLA types are similar are not limited to these.

[0081] Furthermore, based on the user's HLA type, cells with the same or similar HLA type may be extracted from iPS cells stored in the cell preparation management system 20. Furthermore, cells derived from the selected HLA type may be used to verify whether or not the GVHD suppressive effect is exerted.

[0082] In addition, for HLA homozygous users (donor candidates), the number of HLA-matched recipients can also be managed. Furthermore, based on the number of HLA-type-matched recipients, it is also possible to estimate how many cultured cells derived from cells of each donor candidate are required, and to prepare iPS cells of each donor candidate based on the estimated results. In this way, the recipient can plan the preparation of iPS cells and somatic cells in order to receive the somatic cells from HLA-type-matched donors.

[0083] It should be noted that various prediction processes such as health risks and / or HLA compatibility performed by the health risk information management device 10 of the present invention can improve prediction accuracy by utilizing deep learning and / or AI (artificial intelligence).

[0084] It should be noted that the present invention is not limited to the above-mentioned embodiments, and can be implemented in various other forms within the scope of the main purpose of the present invention. Therefore, the above-mentioned embodiments are only illustrative in all aspects and are not to be interpreted in a limiting manner. For example, the above-mentioned processing steps can be changed in order or executed in parallel within the scope that the processing content does not cause contradictions.

Claims

1. A health risk information management device, characterized in that: have: An expected health risk information acquisition unit that acquires information related to the expected health risk of the user; a cultured cell preparation determination unit that determines whether to prepare cultured cells derived from the user's cells based on the information on the expected health risk; a somatic cell type determination unit that determines the type of somatic cells to be prepared from cultured cells derived from cells of the user based on the information on the expected health risk; as well as A recommended examination content determination unit determines the content of an examination to be performed using somatic cells prepared from cultured cells derived from cells of the user in order to verify the expected health risk.

2. The health risk information management device according to claim 1, characterized in that: The predicted health risk information acquisition unit acquires information related to predicted health risks based on information of a user's genetic examination.

3. The health risk information management device according to claim 1 or 2, characterized in that: The health risk information management device comprises: a somatic cell production instruction unit that sends a somatic cell production instruction to a system that manages cell production; and A test result providing unit provides the user with the result of the test performed using the prepared somatic cells.

4. The health risk information management device according to claim 3, characterized in that: The health risk information management device includes a cell preparation necessity confirmation unit, which provides the user with information on somatic cells to be prepared and receives a response from the user as to whether the user wishes to prepare somatic cells. Upon receiving the reply indicating that somatic cells are desired to be prepared, the somatic cell preparation instruction unit transmits the somatic cell preparation instruction to a system that manages preparation of the somatic cells.

5. The health risk information management device according to claim 4, characterized in that: The cell preparation necessity confirmation unit receives a response as to whether or not the cultured cells are desired to be prepared.

6. The health risk information management device according to claim 3, characterized in that: The health risk information management device includes a health risk corresponding information providing unit, which provides information related to preventive measures for the expected health risks of the user and countermeasures when the expected health risks occur based on the results of the examination.

7. The health risk information management device according to claim 6, characterized in that: The health risk corresponding information providing unit provides at least one of information on a drug that is screened using the prepared somatic cells and is effective in improving the expected health risk, or information on the toxicity of the drug and the responsiveness to the drug.

8. The health risk information management device according to claim 6, characterized in that: The health risk corresponding information providing unit provides information on the type of somatic cells that should be prepared in advance from cultured cells derived from the user's cells based on the results of the examination.

9. The health risk information management device according to claim 6, characterized in that: The health risk corresponding information providing unit provides the user with information on somatic cells that should be prepared and stored in advance for future preparation, recommended preparation period, and information quantifying the effect obtained by the preparation of the somatic cells based on the results of the examination.

10. The health risk information management device according to claim 6, characterized in that: The health risk corresponding information providing unit provides information on the cultured cells that the user should prepare and store in advance based on the results of the examination.

11. The health risk information management device according to claim 6, characterized in that: The health risk corresponding information providing unit predicts the period until the health risk occurs based on the result of the examination, and provides information on the required treatment cost and a payment plan corresponding to the period until the occurrence.

12. The health risk information management device according to claim 1, characterized in that: The health risk information management device includes a donor candidate extraction unit, which extracts HLA homozygous users as donor candidates based on the HLA type information of the users, The cultured cell preparation determination unit determines whether to prepare cultured cells derived from cells of the user based on whether the user is HLA homozygous.

13. The health risk information management device according to claim 12, characterized in that: The health risk information management device comprises: a recipient information acquisition unit that acquires information on the HLA type of a recipient who wishes to receive somatic cells from an HLA type-matched donor; and The HLA matching determination unit extracts a donor candidate whose HLA type matches the HLA type of the recipient from among the extracted HLA homozygous donor candidates.

14. The health risk information management device according to claim 13, characterized in that: The health risk information management device includes a compatibility information providing unit that provides the recipient with a compatibility verification result using immune cells derived from the recipient's blood and iPS cells or somatic cells derived from iPS cells of a donor candidate whose HLA type matches the recipient's HLA type.

15. The health risk information management device according to claim 12, characterized in that: The health risk information management device includes a matching person number calculation unit that calculates the number of recipients that are HLA type matched for each donor candidate.

16. The health risk information management device according to claim 12, characterized in that: The health risk information management device includes a donor cell preparation management unit that estimates how many cultured cells derived from cells of each donor candidate are required based on the number of HLA type-matched recipients.

17. The health risk information management device according to claim 13, characterized in that: The HLA matching determination unit extracts HLA type matching cells from the stored cultured cells based on the user's HLA type information.

18. The health risk information management device according to claim 13, characterized in that: The HLA match determination unit determines that there is an HLA type match when a predetermined number of HLA types among a plurality of HLA types match.

19. The health risk information management device according to claim 1, characterized in that: The cultured cells derived from the cells are stem cells.

20. A computer, characterized in that: Performing health risk information management, the health risk information management comprising: Steps to obtain information about anticipated health risks to users; A step of determining whether to prepare cultured cells derived from cells of the user based on the information of the expected health risks; A step of determining the type of somatic cells that should be prepared from cultured cells derived from cells of the user based on the information on the expected health risks; and A step of determining the contents of examinations to be performed using somatic cells prepared from cultured cells derived from cells of the user in order to confirm the expected health risk.

21. A recording medium, characterized in that Stores programs, The program enables the computer to function as an expected health risk information acquisition unit, a cultured cell preparation determination unit, a somatic cell type determination unit, and a recommended examination content determination unit, wherein the expected health risk information acquisition unit acquires information related to the expected health risk of the user, the cultured cell preparation determination unit determines whether to prepare cultured cells derived from the user's cells based on the expected health risk information, the somatic cell type determination unit determines the type of somatic cells that should be prepared from cultured cells derived from the user's cells based on the expected health risk information, and the recommended examination content determination unit determines the content of the examination that should be performed using somatic cells in order to confirm the expected health risk, the somatic cells being prepared from cultured cells derived from the user's cells.

Images